Article
Analytical Testing Strategy for Biologics CMC: A Practical Guide from Candidate Selection to IND Filing
Chemistry, Manufacturing, and Controls is the analytical backbone of every biologics regulatory submission. Many CMC programs generate data reactively for specific submissions, creating constraints that complicate future manufacturing changes. Element's biologics analytical experts explore how a strategic, forward-looking testing approach builds the product knowledge that supports both regulatory success and manufacturing flexibility.
Chemistry, Manufacturing, and Controls represents the foundation of any biologics regulatory submission. Module 3 of regulatory dossiers demands comprehensive analytical data demonstrating product understanding, manufacturing control, and quality consistency. Yet many organizations approach CMC analytical testing reactively, generating data as needed for specific submissions rather than building strategic testing programs that accelerate development.
The analytical testing performed during early CMC development shapes everything that follows. Methods developed now become the specification parameters for commercial manufacturing. Data generated today appear in regulatory submissions years later. Early analytical decisions either enable manufacturing flexibility or create constraints that complicate future changes. Understanding how to build strategic CMC analytical programs makes the difference between smooth regulatory interactions and challenging amendment cycles.
What's the Difference Between CMC Analytical Testing and QC Release Testing?
CMC analytical testing serves fundamentally different purposes than quality control release testing, though they share methods and platforms. This distinction shapes how organizations should approach analytical development during CMC programs.
QC release testing answers a defined question: does this batch meet predetermined specifications? The methods are validated, the acceptance criteria are established, and the goal is confirming quality through standardized procedures. This testing is essential for commercial operations but provides limited product understanding beyond pass/fail determinations.
CMC analytical testing during development builds the product knowledge that informs regulatory submissions and manufacturing control strategies. These programs characterize molecular structure, identify product-related variants, detect process-related impurities, and establish the analytical foundation for future specifications. The goal extends beyond confirming quality to understanding what quality means for this specific molecule manufactured by this specific process.
Building Product Knowledge for Regulatory Submissions
This knowledge-building function directly supports CMC regulatory sections. Module 3.2.S (Drug Substance) requires structural characterization, impurity profiles, and analytical procedures. Module 3.2.P (Drug Product) demands similar data for the final formulated product. Regulatory reviewers evaluate whether analytical data demonstrate adequate product understanding and appropriate control strategies. Comprehensive testing during development generates the data these sections require.
Organizations that treat early analytical work as preliminary QC testing miss opportunities to build CMC knowledge efficiently. Waiting until formal stability studies or process validation to perform comprehensive characterization creates timeline pressure and limits flexibility to adapt methods as understanding develops. Strategic CMC analytical programs front-load characterization work, establishing robust methods and deep product knowledge that support all subsequent regulatory needs.
The Chemistry Section: Structural Characterization Through Analytical Testing
The Chemistry section of CMC submissions (Module 3.2.S.3 for drug substance) requires detailed structural characterization. Regulatory agencies expect confirmation of primary structure, characterization of post-translational modifications, and assessment of higher-order structure. Analytical testing provides all this information.
Primary structure confirmation begins with intact mass analysis using mass spectrometry. This verifies the expected amino acid sequence was expressed correctly. Peptide mapping extends this confirmation by digesting the protein and analyzing fragments, detecting any unexpected sequence variants or modifications. These methods catch manufacturing issues like amino acid substitutions or expression errors that could impact product performance or safety.
Post-translational modifications represent a more complex analytical challenge. Glycosylation patterns significantly affect biologics properties including stability, pharmacokinetics, and immunogenicity. Comprehensive glycan analysis involves releasing glycans from the protein, separating them chromatographically, and identifying structures through mass spectrometry. The resulting glycan profile becomes part of CMC characterization, demonstrating manufacturing control of this critical quality attribute.
Charge variant analysis using ion exchange chromatography or capillary isoelectric focusing reveals heterogeneity from chemical modifications like oxidation, deamidation, or C-terminal lysine variation. Understanding which charge variants are present and at what levels informs specification setting and helps interpret stability data. Methods detecting these variants become essential tools for CMC control strategies.
Higher-order structure assessment presents analytical challenges since protein folding and tertiary structure directly impact biological activity. Techniques like circular dichroism, differential scanning calorimetry, and analytical ultracentrifugation provide insights into protein conformation and thermal stability. While not typically release tests, these methods support CMC submissions by demonstrating appropriate higher-order structure and establishing fingerprints for comparability assessments.
The Manufacturing Section: Process-Related Impurity Testing for Biologics CMC
Manufacturing sections of CMC submissions (Module 3.2.S.2.3 for drug substance) require demonstration that processes adequately remove or control impurities. Analytical testing provides this evidence through methods detecting host cell proteins, residual DNA, process chemicals, and other manufacturing-related contaminants.
Host cell protein (HCP) analysis detects protein impurities from the expression system. ELISA-based methods using polyclonal antibodies against host cell proteins provide quantitative HCP measurement. The sensitivity and coverage of HCP assays significantly impact their regulatory acceptability. CMC submissions need to demonstrate that HCP methods detect a broad range of potential contaminants and achieve appropriate detection limits given the product's route of administration.
Residual DNA testing ensures nucleic acids from the host cells are adequately cleared. Quantitative PCR or hybridization-based methods measure DNA levels, with regulatory expectations varying by product type and administration route. Parenteral products typically require demonstrating DNA levels below 10 nanograms per dose. The analytical methods supporting these claims appear in CMC submissions with validation data demonstrating appropriate sensitivity and accuracy.
Process chemicals like antibiotics used for cell culture selection, leachables from chromatography resins, or residual protein A from purification also require analytical monitoring. The specific methods needed depend on the manufacturing process. CMC analytical programs include testing for process-related impurities relevant to the specific production approach, demonstrating adequate removal through purification.
The analytical data generated for process-related impurities directly support manufacturing control strategy. Demonstrating consistent clearance across development batches enables justification of specifications and informs decisions about which impurities require routine testing versus periodic verification. These data become central to CMC regulatory discussions about manufacturing quality assurance.
What Analytical Tests Are Required for Biologics Specifications and IND Submissions?
ICH Q6B provides guidance on setting specifications for biotechnological products. This framework distinguishes between tests for every batch (identity, purity, potency, etc.) and those performed periodically (extended characterization). CMC analytical programs during development generate the data that informs where to set specification limits and which tests are truly necessary for routine control.
Identity test methods must provide adequate specificity. Simple binding assays may suffice for some products, while others require peptide mapping or other detailed characterization. The identity method chosen for specifications becomes routine commercial testing, so practicality matters alongside scientific appropriateness. Development programs balance comprehensive confirmation against testing throughput requirements.
Purity and impurity testing typically involve multiple orthogonal methods. Size exclusion-based chromatography measures aggregates and fragments. Reversed-phase chromatography detects product-related degradants or impurities. Capillary-based electrophoresis assesses protein size and charge purity. Each method reveals different aspects of product heterogeneity. Specifications include limits for the variants these methods detect, informed by data accumulated during development show normal ranges for the manufacturing process.
Potency assays represent particularly important CMC considerations. Regulatory agencies expect potency methods that measure biological activity relevant to the therapeutic mechanism. Cell-based bioassays often provide this functional assessment, though they can be complex and variable. Binding assays may correlate with potency but generally don't substitute for functional testing. CMC programs invest significant effort developing robust, reproducible potency assays that support specifications and stability programs. However, consistent and routine monitoring of the results are critical to prevent lot release and stability testing failure before they happen, not just of the product, but also of reference standards and critical reagents. In practice, this means building monitoring disciplines before problems emerge rather than after.
How Early Should Stability Testing Begin in a Biologics CMC Program?
ICH Q1 and Q5C provide a general guidance on stability testing, with Q5C specific for biologics. The analytical testing performed in stability studies directly impacts claimed shelf life and storage conditions. Comprehensive stability programs require careful planning during CMC development.
Establishing Stability-Indicating Methods
Stability-indicating methods must detect degradation products relevant to the molecule's degradation pathways. Aggregation, polypeptide hydrolysis, chemical modification such as amidation or deamidation are some common stability concern for proteins, impacting the purity and potency of the product. The specific degradation pathways vary by molecule.
Initial stability studies support IND submissions with data from forced degradation studies, accelerated and ongoing long-term conditions. Real-time data under proposed storage conditions continue to accumulate to support BLA submissions. The analytical testing performed at each timepoint generates the stability profiles that inform shelf life claims, packaging, and storage recommendations. Inadequate analytical methods that miss important degradation changes create regulatory risk and potentially incorrect stability conclusions.
Reference Standard Management for Long-Term Programs
Reference standards management is an important, yet often overlooked, aspect of CMC analytical programs. Primary reference standards require their own qualification, continuous monitoring, and re-qualification activities. Working reference standards used for routine testing need periodic requalification against primary standards. The entire reference standard system requires documentation for CMC submissions, demonstrating appropriate control of these critical materials.
Development organizations sometimes underestimate stability testing requirements for early CMC programs. Initiating stability studies too late delays regulatory submissions when real-time data under proposed storage conditions prove insufficient. Strategic CMC programs start stability testing early, even on non-final material, to begin accumulating the data regulatory submissions eventually require.
Reference Standards and Their Role in Biologics CMC Analytical Programs
Reference standards form the foundation of quantitative analytical testing for biologics. These characterized materials serve as comparators for identity testing, quantitation standards for purity analysis, and controls for potency assays. Because the vast majority of biologics drug substance and drug products are innovative molecules without an existing USP standard, the batch to be used as designated Reference Materials usually comes from in-house and the volume needed must be planned accordingly. CMC regulatory sections require extensive documentation of reference standard qualification and use.
Primary reference standards receive thorough characterization through the full analytical test battery. This extensive testing establishes the reference material's properties and provides data for periodic requalifications and CMC submissions. Primary standards are typically stored under conditions that maintain stability over many years, with periodic reanalysis confirming they remain suitable for use.
Working reference standards used in routine testing are qualified against primary standards. This qualification typically involves side-by-side testing demonstrating equivalence in relevant assays. Working standards may require more frequent requalification depending on storage conditions and stability characteristics. The hierarchy from primary to working standards provides a practical approach to reference material management while maintaining traceability.
In-house reference standards must be thoroughly characterized and controlled even when compendial or commercial reference standards don't exist for a specific molecule. Early CMC programs establish reference standards from well-characterized development lots, documenting their preparation and qualification. These materials support all subsequent analytical testing and appear in CMC submissions as part of the control strategy.
International or pharmacopeial reference standards provide additional value when available. WHO International Standards exist for certain biologics, offering independent reference materials that facilitate global submissions. When available, these standards strengthen CMC packages by demonstrating testing against internationally recognized materials. However, many novel biologics lack such standards, requiring internal reference material programs.
Looking Ahead: Evolving Analytical Expectations for Biologics CMC
Regulatory expectations for biologics characterization continue to develop, and the analytical methods considered sufficient at one stage of the industry's evolution don't always remain so. Organizations that build strategic CMC programs, with comprehensive characterization foundations and well-documented analytical rationale, tend to be better positioned to incorporate emerging approaches as agency expectations evolve, without significant disruption to existing packages. In a development environment where timelines and resources are increasingly stretched, that kind of analytical durability is worth planning for from the start.
Building CMC Analytical Strategies That Support Biologics Manufacturing Flexibility
Strategic CMC analytical development anticipates future manufacturing needs rather than optimizing only for immediate requirements. Manufacturing processes evolve during development through scale-up, equipment changes, and site transfers. Analytical methods that support comparability assessments enable these changes without extensive revalidation or regulatory amendments.
Comprehensive characterization methods developed early serve comparability needs throughout development. When processes change, side-by-side analytical comparison of material made before and after the change demonstrates comparability. Organizations that perform extensive characterization only at specific regulatory milestones lack the analytical foundation for confident comparability assessments when manufacturing evolves.
Analytical methods should be sufficiently robust and well-characterized to transfer between laboratories. Technology transfer to contract manufacturers, contract testing labs, or different company sites requires studies demonstrating comparable results across locations. Methods developed without attention to robustness and transferability create obstacles to transfer should there be a supply chain problem. CMC analytical programs benefit from considering potential future transfers even when immediate plans involve a single testing location.
Platform analytical approaches offer efficiency for organizations working with related molecules. Common methods for identity, purity, potency, and impurity testing across a product pipeline reduce development time and leverage existing expertise. These platforms still require molecule-specific optimization and validation, but the foundation accelerates CMC analytical development compared to developing entirely novel methods for each program.
Element provides comprehensive CMC analytical services for development programs, offering established methods for structural characterization, impurity testing, potency assessment, and ICH-compliant stability studies. For organizations building CMC packages for regulatory submissions, our testing partnerships provide access to the breadth of analytical capabilities and regulatory experience that CMC programs require.
By Engaged Expert
Dr. Khanh Ngo Courtney
Dr. Courtney's experience extends from R&D to analytical method development, validation, implementation, method transfer, and optimization of test methods for the cGMP setting per USP and ICH guidelines. She is the General Manager for Element Ann Arbor, an analytical lab in our Life Sciences business. She is a CMC professional in the Biological therapeutic space, and specializes in applying analytical strategies to meet regulatory intent.
Related Industries
Related Services
Chemistry, Manufacturing and Controls (CMC) & CDMO Testing Services
Element provides specialized analytical testing services designed for CDMOs, offering flexible capacity, regulatory compliance, and advanced capabilities that enable successful client program delivery across all development phases.
Biopharmaceuticals & Biologics Analysis Services
Our clients develop safe, efficacious products with confidence thanks to Element’s Biologics and Advanced Therapy Medicinal Products (ATMPS) testing services.
Analytical Method Development & Validation
Element's regulatory and industry experts have a proven track record of successfully developing and validating fit-for-purpose, accurate, and reliable analytical methods based on established CDER/ICH and FDA guidelines and procedures.
Pharmaceutical Unknown Identification and Impurity Testing
Element offers expert impurity testing services for pharmaceuticals, ensuring drug safety, quality, and compliance with FDA and ICH guidelines through advanced analytical methods and tailored solutions.